Evidence map›Paper›PMID 26004281›Full record

ArticleTranslational stroke research2015

Sequential Therapy with Minocycline and Candesartan Improves Long-Term Recovery After Experimental Stroke.

Sahar Soliman, Tauheed Ishrat, Abdelrahman Y Fouda, Ami Patel, Bindu Pillai, Susan C Fagan

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational stroke research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Sahar SolimanCharlie Norwood VA Medical Center, Augusta, GA, USA.
Tauheed Ishrat
Abdelrahman Y Fouda
Ami Patel
Bindu Pillai
Susan C Fagan
Augusta University · USCharlie Norwood VA Medical Center · USUniversity of Georgia · US

Funding

Mechanisms of Vascular Protection after Acute StrokeR01NS063965 · NINDS · UNIVERSITY OF GEORGIA · PI FAGAN, SUSAN C · 2009 to 2013
$1.4M
Mechanisms and Consequences of Hypertension after StrokeI01BX000891 · VA · CHARLIE NORWOOD VA MEDICAL CENTER · PI FAGAN, SUSAN C · 2011 to 2014
–
BLRD VA I01 BX000891NINDS NIH HHS R01 NS063965NINDS NIH HHS R01-NS063965
6 · The paper itself

Abstract

Minocycline and candesartan have both shown promise as candidate therapeutics in ischemic stroke, with multiple, and somewhat contrasting, molecular mechanisms. Minocycline is an anti-inflammatory, antioxidant, and anti-apoptotic agent and a known inhibitor of matrix metalloproteinases (MMPs). Yet, minocycline exerts antiangiogenic effects both in vivo and in vitro. Candesartan promotes angiogenesis and activates MMPs. Aligning these therapies with the dynamic processes of injury and repair after ischemia is likely to improve success of treatment. In this study, we hypothesize that opposing actions of minocycline and candesartan on angiogenesis, when administered simultaneously, will reduce the benefit of candesartan treatment. Therefore, we propose a sequential combination treatment regimen to yield a better outcome and preserve the proangiogenic potential of candesartan. In vitro angiogenesis was assessed using human brain endothelial cells. In vivo, Wistar rats subjected to 90-min middle cerebral artery occlusion (MCAO) were randomized into four groups: saline, candesartan, minocycline, and sequential combination of minocycline and candesartan. Neurobehavioral tests were performed 1, 3, 7, and 14 days after stroke. Brain tissue was collected on day 14 for assessment of infarct size and vascular density. Minocycline, when added simultaneously, decreased the proangiogenic effect of candesartan treatment in vitro. Sequential treatment, however, preserved the proangiogenic potential of candesartan both in vivo and in vitro, improved neurobehavioral outcome, and reduced infarct size. Sequential combination therapy with minocycline and candesartan improves long-term recovery and maintains candesartan's proangiogenic potential.

Indexed as

Angiotensin II Type 1 Receptor BlockersAnimalsBenzimidazolesBiphenyl CompoundsBrain InfarctionCell MovementCell ProliferationCerebrovascular TraumaDisease Models, AnimalEndothelium, VascularEpithelial CellsHumansHydro-LyasesInfarction, Middle Cerebral ArteryMaleMatrix MetalloproteinasesAngiotensin II Type 1 Receptor BlockersBenzimidazolesBiphenyl CompoundscandesartanHydro-Lyaseslactate dehydrataseMatrix MetalloproteinasesMinocyclineTetrazolesVascular Endothelial Growth Factor A

Identifiers

PMID26004281
PMCPMC4559761
OpenAlexW890748490

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.